1NE0 Stock Chart & Stats
€4.15
-€0.18(-3.70%)
At close: 4:00 PM EDT
€4.15
-€0.18(-3.70%)
Day’s Range― - ―
52-Week Range€2.78 - €7.60
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
€67.43M
Enterprise Value€121.00
Total Cash (Recent Filing)€11.20M
Total Debt (Recent Filing)€1.81M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 09, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding17,178,785
10 Day Avg. Volume0
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.92Price Target Upside187.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.74
Revenue Forecast (FY)€21.35M
Bulls Say, Bears Say
Bulls Say
YCANTH Commercial MomentumRising dispensed units and YCANTH revenue indicate improving prescriber adoption and patient demand for the company’s commercial product. Continued uptake can expand the revenue base and improve operating leverage as Verrica scales its focused dermatology commercial infrastructure.
Strong Product EconomicsGross product margins above 90% demonstrate attractive unit economics for YCANTH and provide substantial contribution potential as sales grow. Margin resilience despite year-over-year compression supports the prospect of better earnings conversion if commercial expansion eventually outpaces fixed operating costs.
Funded Pipeline And Global ExpansionTorii’s substantial funding commitment reduces Verrica’s near-term burden for a major Phase III program while advancing a potential additional indication. Together with international distribution progress, this broadens the company’s future commercial opportunity beyond its current U.S. YCANTH base.
Bears Say
Persistent Losses And Revenue ContractionThe current revenue base remains insufficient to cover operating costs, leaving Verrica materially unprofitable despite high gross margins. Revenue contraction further delays the path to scale economics, while sustained losses can require additional financing and limit the company’s ability to invest flexibly.
Ongoing Cash BurnContinued operating and free-cash-flow consumption means Verrica is not yet self-funding its commercial and clinical activities. Until profitability improves, external capital remains important for maintaining operations and advancing development programs, increasing exposure to financing terms and milestone execution.
Weakened Equity CushionThe sharp reduction in equity leaves less balance-sheet protection against continued operating losses and unexpected costs. Although current debt is modest, the smaller equity cushion reduces financial flexibility and raises the importance of successfully growing revenue or securing additional funding.
Verrica Pharmaceuticals News
1NE0 FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was €2.78 and its highest was €7.60 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is €67.43M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Nov 09, 2026 which is in 46 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -€0.532 earnings per share for the quarter, missing the consensus estimate of -€0.333 by -€0.199.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.43.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -€0.532 in its last earnings report, missing expectations of -€0.333. Following the earnings report the stock price went down -2.668%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:1NE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€11.92 (187.27% Upside)
€11.92 (187.27% Upside)
Blogger Sentiment
Neutral
DE:1NE0 Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth €183.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
1NE0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of clear commercial momentum for YCANTH (robust unit growth, quarter-over-quarter revenue gains, new international distribution, and strong trial progress) and encouraging clinical signals (VP-315 Phase II abscopal effects and active Phase III enrollment for common warts). Offsetting these positives are sizable year-over-year revenue decline driven by last year’s one-time milestone, substantial GAAP and non-GAAP losses, materially higher R&D and SG&A expense, a legal settlement charge, and a relatively modest cash balance that makes the company reliant on a conditional credit facility. Management’s nondilutive financing and Torii’s substantial trial funding materially de-risk near-term liquidity and program funding, but financial outcomes remain contingent on milestone achievement, careful draw decisions, and successful trial readouts.View all DE:1NE0 earnings summaries1NE0 Stock 12 Month Forecast
Average Price Target
€11.92
▲(187.27% Upside)